AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Jul 07, 2021

AbbVie to Host Second-Quarter 2021 Earnings Conference Call

NORTH CHICAGO, Ill., July 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2021 financial results on Friday, July 30, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Jun 29, 2021

Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients

NORTH CHICAGO, Ill., June 29, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that upadacitinib (15 mg or 30 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all secondary endpoints at one-year (week 52) in the Phase 3 ulcerative colitis maintenance study.1 Significantly more upadacitinib-treated patients achieved clinical remission at week 52 compared to placebo (15 mg: 42 percent and 30 mg: 52 percent versus placebo: 12 percent; p<0.001).1

Jun 28, 2021

AbbVie Gastroenterology Pipeline to be Featured at the 16th Congress of European Crohn's and Colitis Organisation (ECCO)

NORTH CHICAGO, Ill., June 28, 2021 /PRNewswire/ -- AbbVie today announced new data on upadacitinib (RINVOQ®) in ulcerative colitis and risankizumab (SKYRIZI®) in Crohn's disease will be presented as oral presentations at the 16th Congress of European Crohn's and Colitis Organisation (ECCO), to be held virtually July 2-3 and July 8-10. AbbVie is presenting a total of nine abstracts, five of which are oral presentations, across a broad range of studies in inflammatory bowel diseases (IBD).

Jun 25, 2021

AbbVie Provides Update Regarding RINVOQ® (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S.

NORTH CHICAGO, Ill., June 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that the FDA will not meet the Prescription Drug User Fee Act (PDUFA) action dates for the supplemental New Drug Applications (sNDAs) for RINVOQ® (upadacitinib) for the treatment of adults with active psoriatic arthritis and adults with active ankylosing spondylitis. The FDA cited its ongoing review of Pfizer's post-marketing study, ORAL Surveillance, evaluating tofacitinib in patients with rheumatoid arthritis.

Jun 25, 2021

CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis

NORTH CHICAGO, Ill., June 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of RINVOQ® (upadacitinib), an oral, selective and reversible JAK inhibitor, for the expanded use in adults (15 mg or 30 mg, once daily) and adolescents 12 years and older (15 mg, once daily) with moderate to severe atopic dermatitis who are candidates for systemic therapy. RINVOQ is being studied in several immune-mediated inflammatory diseases.4-10

Jun 24, 2021

AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma

NORTH CHICAGO, Ill. and NEWARK, Calif., June 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Teneobio, Inc. announced today that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma (R/R MM). In February 2019, AbbVie and TeneoOne entered a strategic transaction to develop and commercialize TNB-383B, a bispecific antibody that simultaneously targets BCMA and CD3 and is designed to direct the body's own immune system to target and kill BCMA-expressing tumor cells. AbbVie exercised its exclusive right to acquire TeneoOne and TNB-383B based on an interim analysis of an ongoing Phase 1 study.  

Jun 17, 2021

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., June 17, 2021 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share. 

Jun 12, 2021

IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study

NORTH CHICAGO, Ill., June 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA® (ibrutinib) plus VENCLEXTA®/VENCLYXTO® (venetoclax) (I+V) versus chlorambucil plus obinutuzumab (C+O) for first-line treatment in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had active disease requiring treatment per the International Workshop on CLL (iwCLL) criteria. The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent review committee (IRC) with a HR 0.216 (95% CI, 0.131-0.357; p < 0.0001), demonstrating a reduction in the risk of disease progression or death for I+V of approximately 78% compared to C+O. I+V is the first all-oral, once-daily, chemotherapy-free, fixed-duration investigational combination. Results of the study will be presented at the European Hematology Association (EHA) 2021 Virtual Congress (Abstract #LB1902) during late-breaking abstract session on June 12 from 4:00-5:30 p.m. CEST.

Jun 11, 2021

New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment

NORTH CHICAGO, Ill., June 11, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a four-year follow-up analysis of the Phase 3 CLL14 trial, which showed that previously untreated patients with chronic lymphocytic leukemia (CLL) with coexisting conditions who were treated with VENCLYXTO®/VENCLEXTA® (venetoclax) plus obinutuzumab continued to show longer progression-free survival (PFS) and higher rates of undetectable minimal residual disease (MRD) compared to patients receiving a standard of care chemoimmunotherapy regimen of obinutuzumab and chlorambucil. The data were presented for the first time today during the virtual 26th European Hematology Association (EHA) Annual Congress (abstract #S146).

Jun 08, 2021

Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign

IRVINE, Calif., June 8, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is changing the way BOTOX® Cosmetic, the #1 selling neurotoxin treatment1, is connecting with consumers. Today, the brand is launching 'See Yourself', a new campaign featuring documentary style shorts that dive deep into the stories of real BOTOX® Cosmetic patients - people of all shapes, sizes, backgrounds, colors, and origins. BOTOX® Cosmetic is the first brand in the category to focus on the unique journeys of its consumers, aiming to create greater transparency and a judgement-free dialogue around the decision to choose an aesthetic treatment for yourself.